Decent reading and a good review although not a lot of new info for those of us that've been on this forum for awhile. There is a nice table showing all the current ongoing US clinical trials.
Br J Clin Pharmacol. 2011 Mar 16. doi: 10.1111/j.1365-2125.2011.03966.x. [Epub ahead of print]
Resveratrol - pills to replace a healthy diet?
Chachay VS, Kirkpatrick CM, Hickman IJ, Ferguson M, Prins JB, Martin JH.
The University of Queensland Diamantina Institute, The University of Queensland*; School of Pharmacy, The University of Queensland*; Centre for Medicine Use and Safety, Faculty of Pharmacy and Pharmaceutical Sciences Monash University**, Department of Nutrition and Dietetics, The Princess Alexandra Hospital*; Mater Medical Research Institute*; School of Medicine Southside, The University of Queensland*.
Abstract
Nutrapharmacology, or the use of bioactive food compounds at pharmacological dose is emerging as a therapeutic approach to target the complex metabolic dysregulations in ageing and obesity-related chronic disease. Resveratrol, a polyphenol found in the skin of grapes, and other edible plants and related food products, has received extensive attention through the link with the French paradox, and later with its chemopreventive activity demonstrated in-vitro and in animal cancer models. A plethora of laboratory investigations has provided evidence for the multi-faceted properties of resveratrol and suggests that resveratrol may target ageing and obesity related chronic disease by regulating inflammation and oxidative stress. A number of obstacles stand in the path to clinical usage however, not least the lack of clinical evidence to date, and the myriad of doses and formulations available. Further, data on the effects of resveratrol consumption in a capsule versus food form is conflicting, and there are uncertain effects of long-term dosing. The review will summarize the human pharmacokinetic and pharmacodynamic published data, and the topics for research if resveratrol is to become a multi-target therapeutic agent addressing chronic disease.
© 2011 The Authors. British Journal of Clinical Pharmacology © 2011 The British Pharmacological Society.
PMID: 21410504
